Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Atara Biotherapeutics (ATRA) has provided an announcement.
Pascal Touchon is set to resign as President and CEO of his company, transitioning to Chairman of the Board after September 9, 2024. He will consult for the company for up to 18 months post-separation. AnhCo Nguyen, with a background in research and development at Fate Therapeutics and Pfizer, will succeed Touchon. Nguyen’s compensation includes a $650,000 base salary, potential bonuses, and a sizeable stock unit award, reflecting the board’s confidence in his ability to lead the company into its next phase.
For an in-depth examination of ATRA stock, go to TipRanks’ Stock Analysis page.